AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.

Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some items rose 10% to $2.17, as expected. Under Chief Executive Officer Pascal Soriot’s watch, Astra has turned into an oncology powerhouse and is increasingly focused on the US. Pascal discusses his company's strong quarterly performance and the state of the pharmaceutical industry with Tim Stenovec and Carol Massar on Bloomberg Businessweek Daily.

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US. Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some items rose 10% to $2.17, as expected. Under Chief Executive Officer Pascal Soriot&rsquo;s watch, Astra has turned into an oncology powerhouse and is increasingly focused on the US. Pascal discusses his company's strong quarterly performance and the state of the pharmaceutical industry with Tim Stenovec and Carol Massar on Bloomberg Businessweek Daily.

Carol Massar and Tim Stenovec bring you reporting from the magazine that helps global leaders stay ahead, plus insight on the people, companies and trends shaping today's complex economy.  Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

Carol Massar and Tim Stenovec bring you reporting from the magazine that helps global leaders stay ahead, plus insight on the people, companies and trends shaping today's complex economy.&nbsp; Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/6db3e5d8-e02c-4634-9d65-b32901577bac/transcript

Advertisement